Left ventricular ejection fraction (EF) of 55% as cutoff for late transition from heart failure (HF) with preserved EF to HF with mildly reduced EF

Circulation Journal

Volumn 79, Issue 10, 2015, Pages 2209-2215

  Ueda, Tomoya ^a   Kawakami, Rika ^a   Nishida, Taku ^a   Onoue, Kenji ^a   Soeda, Tsunenari ^a   Okayama, Satoshi ^a   Takeda, Yukiji ^a   Watanabe, Makoto ^a   Kawata, Hiroyuki ^a   Uemura, Shiro ^a   Saito, Yoshihiko ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cutoff value; Echocardiography; Heart failure; Left ventricular ejection fraction

Indexed keywords

AGED; ANALYTICAL PARAMETERS; ARTICLE; CUTOFF VALUE; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; ECHOCARDIOGRAPHY; EMERGENCY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; CLINICAL TRIAL; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; SYNDROME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; STROKE VOLUME; SYNDROME;

EID: 84942549131     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0425     Document Type: Article

References (28)

1. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: The SOLVD Investigators. N Engl J Med 1992; 327: 685-691
2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
3. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003; 362: 772-776
4. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321
5. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004; 43: 317-327
6. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259
7. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467
8. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population- based study. N Engl J Med 2006; 355: 260-269
9. Somaratne JB, Berry C, McMurray JJ, Poppe KK, Doughty RN, Whalley GA. The prognostic significance of heart failure with preserved left ventricular ejection fraction: A literature-based metaanalysis. Eur J Heart Fail 2009; 11: 855-862
10. Hamaguchi S, Kinugawa S, Sobirin MA, Goto D, Tsuchihashi- Makaya M, Yamada S, et al. Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: Report from the registry of hospitalized heart failure patients. Circ J 2012; 76: 1662-1669
11. Kikuchi S, Wakami K, Goto T, Fukuta H, Sonoda H, Tani T, et al. Clinical significance of abnormal relaxation pattern of the transmitral flow velocity waveform in older patients with preserved left ventricular ejection fraction. Circ J 2013; 77: 2551-2557
12. Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail 2012; 5: 720-726
13. Clarke CL, Grunwald GK, Allen LA, Baron AE, Peterson PN, Brand DW, et al. Natural history of left ventricular ejection fraction in patients with heart failure. Circ Cardiovasc Qual Outcomes 2013; 6: 680-686
14. Ueda T, Kawakami R, Sugawara Y, Okada S, Nishida T, Onoue K, et al. Worsening of renal function during 1 year after hospital discharge is a strong and independent predictor of all-cause mortality in acute decompensated heart failure. J Am Heart Assoc 2014; 3: e001174, doi:10.1161/JAHA.114.001174
15. Ueda T, Kawakami R, Horii M, Sugawara Y, Matsumoto T, Okada S, et al. High mean corpuscular volume is a new indicator of prognosis in acute decompensated heart failure. Circ J 2013; 77: 2766-2771
16. Ueda T, Kawakami R, Nishida T, Onoue K, Soeda T, Okayama S, et al. Plasma renin activity is a strong and independent prognostic indicator in patients with acute decompensated heart failure treated with renin-angiotensin system inhibitors. Circ J 2015; 79: 1307-1314
17. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993; 22: 6A-13A.
18. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology: Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847
19. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: Prevalence, therapies, and outcomes. Circulation 2012; 126: 65-75
20. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: Insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 2009; 119: 3070-3077
21. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: e240-e327, doi:10.1161/CIR.0b013e31829e8776
22. Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009; 54: 410-418
23. Garcia EH, Perna ER, Farias EF, Obregon RO, Macin SM, Parras JI, et al. Reduced systolic performance by tissue Doppler in patients with preserved and abnormal ejection fraction: New insights in chronic heart failure. Int J Cardiol 2006; 108: 181-188
24. Kaku K, Takeuchi M, Otani K, Sugeng L, Nakai H, Haruki N, et al. Age- and gender-dependency of left ventricular geometry assessed with real-time three-dimensional transthoracic echocardiography. J Am Soc Echocardiogr 2011; 24: 541-547
25. Chung AK, Das SR, Leonard D, Peshock RM, Kazi F, Abdullah SM, et al. Women have higher left ventricular ejection fractions than men independent of differences in left ventricular volume: The Dallas Heart Study. Circulation 2006; 113: 1597-1604
26. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007; 50: 768-777
27. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003; 362: 777-781
28. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383-1392.